Paul J. Ross
Active 1982–2025
- 75
- Papers
- 19,983
- Citations
- 55
- h-index
- 74
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine80%
- Biochemistry, Genetics and Molecular Biology12.5%
- Immunology and Microbiology2.7%
- Materials Science1.1%
- Engineering1.1%
- Agricultural and Biological Sciences0.7%
- Other1.9%
Topics
- Hepatocellular Carcinoma Treatment and Prognosis9.2%
- Pancreatic and Hepatic Oncology Research7.9%
- Cholangiocarcinoma and Gallbladder Cancer Studies7.7%
- Cancer Immunotherapy and Biomarkers3.5%
- Cancer Mechanisms and Therapy2.9%
- Gallbladder and Bile Duct Disorders2.9%
- Other65.9%
Coauthors
- David Cunningham30
- Daniel H. Palmer17
- Juan W. Valle16
- Harpreet Wasan13
- Yuk Ting12
- A. Norman11
- Stephen Falk11
- Timothy Iveson11
- Jonathan Wadsley10
- Ian Chau9
- Tim Meyer9
- John Bridgewater8
- Tamas Hickish8
- Alan Anthoney7
- Gary Middleton6
- Mark Hill6
- Richard Hubner6
- Bengt Glimelius5
- J. Oates5
- Janet Graham5
- Justin S. Waters5
- Kinnari Patel5
- Paula Ghaneh5
- Philippe Merle5
All papers
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han - The Lancet 2016 cited by 3,663
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Authors: John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh, Eftychia Eirini Psarelli, Juan W. Valle, Christopher Halloran, Olusola Olusesan Faluyi, Derek O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R. Izbicki, Gary Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W. Büchler - The Lancet 2017 cited by 1,928
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
Authors: John N Primrose, Richard Fox, Daniel H. Palmer, Hassan Malik, Rajendra Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul J. Ross, Lucy Wall, Jonathan Wadsley, JEFF EVANS, Deborah Stocken, Raaj Praseedom, Yuk Ting, Brian R Davidson, John P. Neoptolemos, Timothy Iveson, James Raftery, Shihua Zhu, David Cunningham, O. James Garden, Clive Stubbs, Juan W. Valle, John Bridgewater, John Primrose, RP Fox, Helen Morement, Oscar S.H. Chan, C. Rees, Ma Yt, Tamas Hickish, Stephen Falk, Meg Finch-Jones, Ian Pope, Pippa Corrie, Tom Crosby, S. Sothi, K Sharkland, Douglas Adamson, Lucy Wall, JEFF EVANS, John Dent, U. Hombaiah, Chinenye Iwuji, Alan Anthoney, John Bridgewater, David Cunningham, Roopinder Gillmore, Paul J. Ross, S. Slater, Harpreet Wasan, Jill Waters, Juan W. Valle, Daniel H. Palmer, Hafiz Malik, John P. Neoptolemos, Olusola Olusesan Faluyi, Kate Sumpter, U. Dernedde, S Maduhusudan, G. Cogill, Caroline Archer, Timothy Iveson, Jonathan Wadsley, Suzanne Darby, Mike Peterson, AA Mukhtar, JG Thorpe, Adrian C Bateman, D. Tsang, S. Cummins, L. Nolan, Éric Beaumont, Rajendra Prasad, D. Mirza, Deborah Stocken, Raaj Praseedom, Brian R Davidson, James Raftery, Shihua Zhu, James Garden, C Stubbs, Fareeda Y. Coxon - The Lancet Oncology 2019 cited by 1,228
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Authors: Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle - The Lancet Oncology 2021 cited by 749
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Authors: Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, Andrew Dean, Yan‐Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, J.F. Blanc, Richard Hubner, Chang‐Fang Chiu, Gilberto Schwartsmann, Jens T. Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D. Von Hoff, Li‐Tzong Chen, Clarence S. Adoo, T Anderson, Jamil Asselah, Alan A. Azambuja, Carolyn Bampton, Carlos H. Barrios, Tanios Bekaii‐Saab, Bohuslav Melichar, David Chang, Jen‐Shi Chen, Yeu‐Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csőszi, Antonio Cubillo, Linda C. DeMarco, Maike de Wit, Tomislav Dragovich, W. Jeff Edenfield, Luis Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Vincenzo Iaffaioli, Jitka Jakesova, Zsuzsanna Kahán, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, István Láng, Fa-Chyi Lee, Kuan‐Der Lee, Lara Lipton, Wen Wee, László Mangel, Raul Mena, Daniel H. Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gállego, Cooray Prasad, Kun‐Ming Rau, Jean‐Luc Raoul, Donald Richards, Paul J. Ross, Luís Alberto Schlittler, Martin Šmakal, V. Stahalova, Cora N. Sternberg, Thomas Seufferlein, Niall C. Tebbutt, J. Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong - The Lancet 2015 cited by 1,200
- Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
Authors: Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi, Richard Jackson, Christopher Halloran, Charlotte Rawcliffe, Rajaram Sripadam, Somnath Mukherjee, Zahir Soonawalla, Jonathan Wadsley, Ahmed Al-Mukhtar, Euan J. Dickson, Janet Graham, Long R. Jiao, Harpreet Wasan, Iain S. Tait, Andreas Prachalias, Paul J. Ross, Juan W. Valle, Derek O’Reilly, Bilal Al‐Sarireh, Sarah Gwynne, Irfan Ahmed, Kate Connolly, Kein-Long Yim, David Cunningham, Thomas Armstrong, Caroline Archer, Keith Roberts, Yuk Ting, Christoph Springfeld, Christine Tjaden, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos - The Lancet. Gastroenterology & hepatology 2022 cited by 325
- Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Authors: Tim Meyer, Richard Fox, Yuk Ting, Paul J. Ross, Martin W. James, Richard Sturgess, Clive Stubbs, Deborah Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T.R. Jeffry Evans, Peter L. Collins, Richard Hubner, David Cunningham, John Primrose, Philip J. Johnson, Daniel H. Palmer - The Lancet. Gastroenterology & hepatology 2017 cited by 497
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Authors: Gary Middleton, Paul Silcocks, Trevor F. Cox, Juan W. Valle, Jonathan Wadsley, David Propper, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom Roques, David Cunningham, Stephen Falk, Nick Wadd, Mark Harrison, Pippa Corrie, Timothy Iveson, Angus Robinson, Karen McAdam, Martin Eatock, JEFF EVANS, Caroline Archer, Tamas Hickish, Angel Garcia-Alonso, M. Nicolson, William P. Steward, Alan Anthoney, William Greenhalf, Victoria Shaw, Eithne Costello, Dean J. Naisbitt, Charlotte Rawcliffe, Gemma Nanson, John P. Neoptolemos - The Lancet Oncology 2014 cited by 374
- Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma
Authors: Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson, Paula Ghaneh, Christopher Halloran, Daniel H. Palmer, Fiona Campbell, Juan W. Valle, Olusola Olusesan Faluyi, Derek O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R. Izbicki, Gary Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Markus M. Lerch, Julia Mayerle, Christine Tjaden, Oliver Strobel, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos, for the European Study Group for Pancreatic Cancer - JAMA Surgery 2019 cited by 273
- Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Authors: Joris van de Haar, Xuhui Ma, Salo Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul J. Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, N. Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F.A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri - Nature Medicine 2023 cited by 84
- Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Authors: Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso, Maria Passhak, Hao‐Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stintzing, Kathryn Towns, Tae Won Kim, Kai‐Keen Shiu, Juan Cundom, Sumitra Ananda, A. A. Lebedinets, Rong Fu, Rishi Jain, David E. Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Élez, the LEAP-017 Investigators, Juan Cundom, Ezequiel Slutsky, Julieta Grasselli, Luis Fein, Luciana Bella Quero, Warren Joubert, Peter Gibbs, Timothy Price, Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross and 13 more - Journal of Clinical Oncology 2024 cited by 77
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Authors: Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Paul J. Ross, Armando Santoro, Flair José Carrilho, Jordi Bruix, Shukui Qin, Paul J. Thuluvath, Josep M. Llovet, Marie-Aude LeBerre, Markus Jensen, Gerold Meinhardt, Yoon‐Koo Kang - Journal of Clinical Oncology 2014 cited by 577
- ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer
Authors: Eric Van Cutsem, Julien Taı̈eb, Rona Yaeger, Takayuki Yoshino, Axel Grothey, Evaristo Maiello, Elena Élez, Jeroen Dekervel, Paul J. Ross, Ana Ruiz‐Casado, Janet Graham, Takeshi Kato, J.C. Ruffinelli, Thierry André, E. Carriere Roussel, Isabelle Klauck, M. Groc, Jean-Claude Vedovato, Josep Tabernero - Journal of Clinical Oncology 2023 cited by 94
- Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Authors: Zhenggang Ren, Michel Ducreux, Ghassan K. Abou‐Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assénat, Sheng Hu, Lorenza Rimassa, Tao� Zhang, Jean‐Frédéric Blanc, Hongming Pan, Paul J. Ross, Chia‐Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming‐Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann‐Lii Cheng - Liver Cancer 2022 cited by 78
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Authors: Juan W. Valle, Harpreet Wasan, Andre Lopes, Alison Backen, Daniel H. Palmer, Karen Morris, Marian Duggan, David Cunningham, Alan Anthoney, Pippa Corrie, Srinivasan Madhusudan, Anthony Maraveyas, Paul J. Ross, Justin S. Waters, W P Steward, Charlotte Rees, Sandy Beare, Caroline Dive, John Bridgewater - The Lancet Oncology 2015 cited by 280
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
Authors: John Bridgewater, S. Pugh, Tom Maishman, Zina Eminton, J. M. MELLOR, Amy Whitehead, Louise Stanton, M Radford, Andrea Corkhill, Gareth Griffiths, Stephen Falk, Juan W. Valle, Derek O’Reilly, Ajith K. Siriwardena, Joanne Hornbuckle, Myrddin Rees, Timothy Iveson, Tamas Hickish, O. James Garden, David Cunningham, Tim Maughan, John N Primrose, Alaaeldin Shablack, Ann O’Callaghan, Anne Marie Moody, Alex Allen, A. Brewster, Alison Brown, Astrid Mayer, Brian R Davidson, Chan Ton, Charles Wilson, C. Lowdell, Charlotte Rees, Christopher Baughan, Clare Barlow, Colin Purcell, David Smith, David Tsang, Ewan Brown, Georgina Walker, Hassan Malik, Iain Cameron, Luke Nolan, Marcia Hall, Marjorie Tomlinson, Mark Hill, Mark Peterson, Meg Finch-Jones, Nagappan Kumar, N D Karanjia, Nasim Ali, Nigel Heaton, Nua Chan Ton, Paul J. Ross, Raaj Praseedom, Robert Thomas, Sally Clive, Sarah Slater, Sarah Smith, Satvinder Mudan, Satya Bhattacharya, Sharadah Essapen, Sherif Raouf, Stephen W. Fenwick, Susan Cleator, Tom Diamond, Vanessa Potter - The Lancet Oncology 2020 cited by 239
- Guidance on the management of diarrhoea during cancer chemotherapy
Authors: Jervoise Andreyev, Paul J. Ross, Clare Donnellan, Elaine Lennan, Pauline Leonard, Caroline Waters, Linda Wedlake, John Bridgewater, Rob Glynne‐Jones, William Allum, Ian Chau, Richard H. Wilson, David Ferry - The Lancet Oncology 2014 cited by 255
- Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Authors: Paul J. Ross, S. Ashley, A. Norton, K. Priest, Justin S. Waters, Tim Eisen, Ian E. Smith, Mary O’Brien - British Journal of Cancer 2004 cited by 477
- Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
Authors: Ángela Lamarca, Paul J. Ross, Harpreet Wasan, Richard Hubner, Mairéad G. McNamara, Andre Lopes, Prakash Manoharan, Daniel G. Palmer, John Bridgewater, Juan W. Valle - JNCI Journal of the National Cancer Institute 2019 cited by 165
- The role of the PI3K pathway in colorectal cancer
Authors: D. Papadatos-Pastos, Roy Rabbie, Paul J. Ross, Debashis Sarker - Critical Reviews in Oncology/Hematology 2014 cited by 127
- Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer
Authors: Connie Yip, Vicky Goh, Andrew Davies, James Gossage, Rosalind Mitchell-Hay, O. Hynes, Nick Maisey, Paul J. Ross, Andrew Gaya, David Landau, Gary Cook, Nyree Griffin, Robert M. Mason - European Radiology 2014 cited by 226
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Authors: Harpreet Wasan, Peter Gibbs, Navesh Sharma, Julien Taı̈eb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S. Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, F. Lofts, Sarah Lowndes, Astrid Mayer, Matthew S. Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, R. Muirhead, Andreas Polychronis, Colin Purcell, Paul J. Ross, Ricky A. Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael D. Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi‐Jen Chen, P. Chevallier, Michael Chuong, Stephen Clarke, Andrew L. Coveler, M Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas W. Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Melita A. Gordon, Kate Gregory, Seza A. Güleç, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew P. Holtzman, Richard Isaacs, Christopher Jackson and 156 more - The Lancet Oncology 2017 cited by 398
- Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Authors: Ghassan K. Abou‐Alfa, Óscar Puig, Bruno Daniele, Masatoshi Kudo, Philippe Merle, Joong‐Won Park, Paul J. Ross, Jean-Marie Péron, Oliver Ebert, Stephen L. Chan, Tung Ping Poon, M. Colombo, Takuji Okusaka, Baek‐Yeol Ryoo, Beatriz Mínguez, Takayoshi Tanaka, Toshihiko Ohtomo, Stacey M. Ukrainskyj, Frédéric Boisserie, Olga Rutman, Ya-Chi Chen, Chao Xu, Eliezer Shochat, Lori Jukofsky, Bernhard Reis, Gong Chen, Laura Di Laurenzio, Ray Lee, Chia-Jui Yen - Journal of Hepatology 2016 cited by 127
- Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: David J. Pinato, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Alexandra Emilia Schlaak, Ciro Celsa, Saskia Killmer, Jesús Miguéns Blanco, Caroline Ward, Charalampos‐Vlasios Stikas, Mark R. Openshaw, Nicole Acuti, Georgios Nteliopoulos, Cristina Balcells, Hector C. Keun, Robert Goldin, Paul J. Ross, Alessio Cortellini, Robert Thomas, Anna-Mary Young, Nathan Danckert, Paul Tait, Julian R. Marchesi, Bertram Bengsch, Rohini Sharma - Clinical Cancer Research 2024 cited by 24
